Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health Companies (NYSE/TSX: BHC) has announced its participation in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida. The event is scheduled for Monday, February 24, 2025, at 8:45 a.m. EST.
The company will provide a live audio webcast of the event, which will be accessible through the Investor Relations section of Bausch Health's website. Interested parties can access the webcast at http://ir.bauschhealth.com/events-and-presentations. A replay of the event will be made available on the same investor relations website after the conference.
Bausch Health (NYSE/TSX: BHC) and its GI business, Salix Pharmaceuticals, have announced their 2025 Salix Gastrointestinal Health Scholars Program. The initiative will provide ten scholarships of up to $10,000 each to students living with GI diseases who are pursuing higher education.
This marks the sixth consecutive year of the program, which supports students attending two- or four-year colleges, universities, or advanced vocational/technical schools for the 2025-2026 academic year. The scholarships are available in three categories: Undergraduate Scholar Awards, Graduate Scholar Awards, and Working and/or Single Parents Scholar Awards.
Applicants must complete an online application, submit reference letters, and write an essay about their GI condition's impact on their life and their healthcare provider's role. The application period closes on May 5, 2025, with winners to be announced in summer 2025.
Bausch Health (NYSE/TSX: BHC) has provided an update regarding the potential sale of its Bausch + Lomb subsidiary, which was initially disclosed in December 2024. During the second half of 2024, while exploring liability management alternatives, Bausch + Lomb received an acquisition offer from a private equity firm. However, both companies' boards determined the offer didn't reflect Bausch + Lomb's long-term value and decided not to proceed with the sale.
Bausch Health will maintain its 88% ownership stake in Bausch + Lomb and continue working on liability management alternatives, including new debt financing. The company highlighted strong business performance in 2024, having raised its full-year guidance for revenue, adjusted EBITDA, and adjusted operating cash flow in October 2024. Fourth quarter and full-year 2024 earnings, along with 2025 guidance, will be reported on February 19, 2025.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has scheduled the release of its fourth quarter and full year 2024 financial results for Wednesday, February 19, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. U.S. EST on the same day to discuss the results and provide a business update.
Interested parties can access all materials through the Investor Relations section of Bausch Health's website. A replay of the conference call will be made available on the investor relations website. To participate in the live Q&A session, participants must register in advance through the provided link.
Bausch Health (NYSE/TSX: BHC) announced that XIFAXAN® (rifaximin) 550 mg tablets has been selected by the Centers for Medicare and Medicaid Services (CMS) for the second round of price negotiations under the Inflation Reduction Act. The negotiated pricing will take effect in 2027.
The company plans to engage with CMS to demonstrate XIFAXAN's healthcare system value, highlighting recommendations from The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), which gave XIFAXAN® their highest recommendation (Grade I, A,1) in practice guidelines.
Bausch Health Companies (NYSE/TSX: BHC) has confirmed it is exploring potential sale options for its subsidiary Bausch + Lomb (NYSE/TSX: BLCO) as one of several alternatives to complete their separation. The statement was issued in response to a request from the Canadian Investment Regulatory Organization (CIRO) due to stock volatility concerns related to market rumors.
The company emphasized that while the Board of Directors has authorized management to explore a potential sale, no decision has been made to proceed with any particular transaction, and there is no guarantee that the process will result in a deal. The company stated it will not provide additional details until further disclosure becomes appropriate or necessary.
Bausch Health (NYSE/TSX:BHC) and its GI business, Salix Pharmaceuticals, along with major health organizations, are commemorating the second annual Opioid-Induced Constipation (OIC) Awareness Day on December 5, 2024. The initiative aims to raise awareness about OIC, a common side effect of opioid treatment.
According to statistics, approximately 21% of U.S. adults experienced chronic pain in 2021, with 22% of chronic pain patients receiving opioid prescriptions in 2019. To support the cause, Salix has updated the OICAwarenessDay.com website with resources for healthcare providers, patients, and caregivers. The campaign includes partnerships with influencers, a content program with Chronicon, and social media engagement using hashtags #OICAwarenessDay and #vOICesOfOIC.
Bausch Health (NYSE/TSX:BHC) has appointed Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. Dr. Sadeh brings over 20 years of experience in clinical research and drug development, most recently at Bristol-Meyers Squibb where he served as Senior Vice President and Global Programs Head. His track record includes multiple drug approvals in dermatology and gastroenterology. Dr. Sadeh holds a master's degree from Harvard Medical School and a medical degree from Mount Sinai School of Medicine, with previous experience at Sanofi, Astra-Zeneca, and Schering-Plough.
Bausch Health and Salix Pharmaceuticals announced the presentation of their RED-C Phase 3 clinical trial program at AASLD. The study evaluates a next-generation soluble solid dispersion (SSD) immediate-release rifaximin product designed to delay the onset of first overt hepatic encephalopathy (OHE) hospitalization in cirrhosis patients. The program consists of two global Phase 3 trials involving over 1,000 patients across 398 study sites in 17 countries. Patient enrollment is complete, with efficacy and safety results pending. The therapeutic aims to enhance gastrointestinal luminal solubility while limiting systemic exposure, addressing an unmet medical need as there are currently no approved medications for primary prophylaxis of OHE in cirrhosis.
Bausch Health Canada announced positive reimbursement recommendations from Canada's Drug Agency (CDA) and Quebec's INESSS for PrCABTREO, their triple-combination topical treatment for acne vulgaris. The gel, containing clindamycin phosphate, adapalene, and benzoyl peroxide, is approved for patients 12 years and older. As the first and only triple-combination topical acne treatment approved by Health Canada, CABTREO combines three mechanisms of action. The company will now work with the pan-Canadian Pharmaceutical Alliance to finalize reimbursement terms for Canada's public drug plans. The prescription therapy is currently available through pharmacies across Canada.